Copyright
©The Author(s) 2021.
World J Clin Cases. Jul 16, 2021; 9(20): 5408-5419
Published online Jul 16, 2021. doi: 10.12998/wjcc.v9.i20.5408
Published online Jul 16, 2021. doi: 10.12998/wjcc.v9.i20.5408
Ref. | Patients (n) | Treatment | Treatment duration | Response to treatment |
Hendel et al[63], 1992 | 25 | Omeprazole 20-80 mg (adjustments of the maintenance dose of omeprazole | Mean time of 40 mo | Healing of esophagitis in almost 50% patients |
Marie et al[34], 2006 | 133 | Omeprazole 20-40 mg | Mean duration of 6 yr from treatment initiation | Heartburn (n = 103; 77.4%), dysphagia (n = 19; 14.3%) |
Improvement of heartburn: (77.4%) | ||||
Improvement of dysphagia: (14.3%) | ||||
Esophagitis healing: 32.3% | ||||
Pakozdi et al[64], 2009 | 21 | Lansoprazole 30 mg | 12 mo | Short-term (6 mo) efficacy in decreasing frequency of symptoms in |
No long-term benefit | ||||
Muro et al[65], 2009 | 84 | Rabeprazole 10 mg | 8 wk | Effective for the symptom control |
Foocharoen et al[67], 2017 | 148 | Omeprazole 20 bid | 4 wk | 40.1% responded to omeprazole |
88 | Omeprazole + domperidone (n = 38)/aglycon (n = 37) | Domperidone and algycon are equally effective treatments when used in combination with omeprazole | ||
17% of patients were nonresponsive | ||||
Stern et al[55], 2018 | 38 | Twice daily different PPIs (rabeprazole, dexlansoprazole, esomeprazole, omeprazole, lansoprazole, pantoprazole)-variable dosing schedules | Treatment duration not given | Despite PPIs high-dose: |
61% of SSc patients had an AET ≥ 4.5% | ||||
55% of SSc patients had an AET > 6% | ||||
Foocharoen et al[54], 2020 | 243 | Omeprazole 20 mg bid | 4 wk | PPI-partial response: 53.9% |
Tabuchi et al[72], 2021 | 15 (14/15 with PPI-partial response) | Vonoprazan 10-20 mg | > 2 yr | Symptom relief in 83.4% |
Long-term symptom control in 87% | ||||
Johnson et al[77], 1987 | 12 | Metoclopramide 10 mg Χ 2 | 1 wk from treatment initiation | Significant reduction of reflux events: in 91.6% |
All but 2 patients attained LES pressure values that fell in the normal range after metoclopramide treatment | ||||
Karamanolis et al[84], 2016 | 22 | Buspirone 20 mg | 4 wk | Improvement in the severity of heartburn: 70% |
Improvement in the severity of regurgitation in 58% | ||||
Improvement in dysphagia in 50% and in chest pain in 25% |
- Citation: Voulgaris TA, Karamanolis GP. Esophageal manifestation in patients with scleroderma. World J Clin Cases 2021; 9(20): 5408-5419
- URL: https://www.wjgnet.com/2307-8960/full/v9/i20/5408.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i20.5408